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Abstract: The Kelch-like ECH-associated protein 1 (Keap1)/nuclear factor erythroid 2-related 
factor 2 (Nrf2)/antioxidant response elements pathway enables cells to survive oxidative stress 
conditions through regulating the expression of cytoprotective enzymes such as NAD(P)H:quinone 
oxidoreductase 1 (NQO1). This work presents the design and synthesis of novel anilinoqui-
nazoline derivatives (2–16a) and evaluation of their NQO1 inducer activity in murine cells. 
Molecular docking of the new compounds was performed to assess their ability to inhibit Keap1–
Nrf2 protein–protein interaction through occupying the Keap1–Nrf2-binding domain, which 
leads to Nrf2 accumulation and enhanced gene expression of NQO1. Docking results showed 
that all compounds can potentially interact with Keap1; however, 1,5-dimethyl-2-phenyl-4-(2-
phenylquinazolin-4-ylamino)-1,2-dihydropyrazol-3-one (9), the most potent inducer, showed 
the largest number of interactions with key amino acids in the binding pocket (Arg483, Tyr525, 
and Phe478) compared to the native ligand or any other compound in this series.
Keywords: Kelch domain, molecular modeling, Keap1/Nrf2, cytoprotection, NQO1 
induction
Introduction
Antioxidants, from a chemical viewpoint, are considered electron donors to free 
radicals, molecular centers that tend to lose electrons initiating oxidations, and thus 
protecting the cells against oxidative stress.1–3 Such oxidative stress situations, gener-
ated from imbalanced production of reactive oxygen species, for example, superoxide 
anion radical and hydrogen peroxide, are unfortunately associated with many patho-
logical conditions including stroke, diabetes, Alzheimer’s disease, cancer, and chronic 
inflammation.4 As a natural mechanism to counteract oxidative stress, aerobic cells 
express superoxide dismutase converting superoxide to hydrogen peroxide, which 
is subsequently disposed of catalase and peroxidases. In addition to these enzymatic 
defenses, there are indirect antioxidants, namely, the cytoprotective enzymes, that 
catalyze a wide variety of chemical reactions, protecting cells and organisms and allow-
ing their adaptation to many types of stress.5 Among the most critical cytoprotective 
enzymes is the Kelch-like ECH-associated protein 1 (Keap1)–nuclear factor erythroid 
2-related factor 2 (Nrf2)–antioxidant response elements (AREs) pathway.6,7 The Keap1/
Nrf2/ARE pathway enables the cells to adapt and survive oxidative and inflammatory 
stress conditions through regulating the expression of a network of .100 genes. This 
pathway is inducible by various stress stimuli and small molecules (termed inducers), 
whereby the inducers react with specific cysteine residues of the protein sensor Keap1, 
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which loses its ability to target Nrf2 for ubiquitination and 
proteasomal degradation, resulting in its stabilization, fol-
lowed by binding to the ARE and transcriptional activation 
of downstream target genes, such as NAD(P)H:quinone 
oxidoreductase 1 (NQO1).6,8–11 Recently, the Keap1–Nrf2 
protein–protein interaction has been viewed as a critical target 
for intervention and potential management of a variety of 
oxidative stress-related pathologies, including cancer, Par-
kinson’s and Alzheimer’s disease, and diabetes.12–15 Design 
of noncovalent small-molecule modulators of the Keap–Nrf2 
interaction has been intensively explored.16,17 Quinazoline 
derivatives are considered excellent bioactive substances 
where a number of biological activities have been associated 
with antioxidant activity.18–20
In continuation of our work toward identification of 
NQO1 inducers,21,22 we herein report the synthesis, NQO1 
inducer activity, and Keap1 binding in silico screening results 
for a novel class of anilinoquinazolines.
Materials and methods
chemistry
Melting points (uncorrected) were determined in open capillar-
ies on a Gallen Kamp melting point apparatus (Gallemkamp, 
MSE Ltd., London, UK). Precoated silica gel plates (Kieselgel 
0.25 mm, 60 G F254; EMD Millipore, Billerica, MA, USA) 
were used for thin layer chromatography. A solvent system 
of chloroform/methanol mixture (8:2 mL) was used as a 
developing system, and the spots were detected by ultraviolet 
light. Infrared (IR) spectra (KBr disk) were recorded using 
a Perkin Elmer FT-IR spectrophotometer (PerkinElmer Inc., 
Waltham, MA, USA). Nuclear magnetic resonance (NMR) 
spectra were scanned on a Bruker NMR spectrophotometer 
(Bruker AXS Inc., Madison, WI, USA), operating at 500 MHz 
for 1H spectra and 125.76 MHz for 13C spectra. Chemical shifts 
are expressed in δ-values (ppm) relative to tetramethylsilane 
as an internal standard, using dimethyl sulfoxide (DMSO)-d
6
 
as a solvent. Elemental analyses were done on a model 2400 
Perkin Elmer CHNSO analyzer (PerkinElmer Inc.). All 
the values were within ±0.4% of the theoretical values. All 
reagents used were of analytical reagent grades. The starting 
material 4-chloro-2-phenylquinazoline 1 was purchased from 
Sigma-Aldrich Co. (St Louis, MO, USA) and was directly 
used for preparation of the target compounds.
general procedure for the synthesis of 
2-phenyl-quinazoline-4-amine derivatives 
(2–16a)
Compound 1 (2.40 g, 0.01 mol) and different amines 
(0.012 mol) were added to dry dimethylformamide (10 mL) 
containing three drops trimethylamine. Reaction mixture was 
refluxed for 24 hours, and solid product formed was filtrated 
and recrystallized from acetic acid to give 2–16a.
n-heptyl-2-phenylquinazolin-4-amine (2)
Yield, 87%; melting point (mp) 141°C–143°C. IR (cm−1): 3,278 
(NH), 3,074 (aromatic [arom]), 2,924, 2,950, 2,851 (aliphatic 
[aliph]), 1,639 (CN). 1H NMR: δ 0.9 (t, 3H, CH
3
), 1.2 [m, 10H, 
5CH
2
], 3.8 [t, 2H, CH
2
-NH], 7.6–8.7 [m, 9H, Ar-H], 10.8 [s, 
1H, NH]. 13C NMR: δ 14.3, 22.5, 26.8, 28.9, 31.5, 31.6, 42.1, 
112.6, 120.3, 124.8 (2), 128.2, 129.3, 129.5, 131.7, 133.8, 
135.5, 139.5, 157.3, 160.2. Mass spectroscopy (MS) m/z (%): 
319 (M+) (3.23), 204 (100). Calculated for C
21
H
25
N
3
 (319): C, 
78.96; H, 7.89; N, 13.15. Found: C, 78.59; H, 8.13; N, 12.81.
N-(Octan-2-yl)-2-phenylquinazolin-4-amine (3)
Yield, 80%; mp 192°C–193°C. IR (cm−1): 3,191 (NH), 3,100 
(arom), 2,954, 2,925, 2,850 (aliph), 1,629 (CN). 1H NMR: δ 
0.7 [t, 3H, CH
3
], 0.8 [d, 3H, CH
3
, J=7.2 Hz], 1.2–1.8 [m, 10H, 
5CH
2
], 2.8 [m, 1H, CH], 7.6–8.8 [m, 9H, Ar-H], 10.0 [s, 1H, 
NH]. 13C NMR: δ 14.3, 20.3, 21.2, 25.8, 28.8, 31.6, 36.4, 48.6, 
112.5, 120.4, 124.9 (2), 128.2, 129.4, 129.6 (2), 131.9, 133.8, 
136.0, 157.5, 159.8, 160.6. MS m/z (%): 333 (M+) (12.7), 255 
(100). Calculated for C
22
H
27
N
3
 (333.47): C, 79.24; H, 8.16; 
N, 12.60. Found: C, 79.50; H, 7.84; N, 12.25.
2-Phenyl-N-(2-(pyrrolidin-1-yl)ethyl)quinazolin-4-
amine (4)
Yield, 90%; mp 193°C–194°C. IR (cm−1): 3,325 (NH), 358 
(arom), 2,935, 2,846 (aliph), 1,617 (CN). 1H NMR: δ 1.4–1.5 
[m, 4H, CH
2
-CH
2
 Cyclo], 2.4–2.5 [m, 4H, CH
2
-N-CH
2
 
Cyclo], 2.6 [t, 2H, N-CH
2
], 3.8 [t, 2H, CH
2
-NH], 7.8–8.5 [m, 
10H, Ar-H + NH]. 13C NMR: δ 24.5 (2), 40.5, 54.7, 57.7 (2), 
114.3, 123.0, 125.6 (2), 128.3, 128.6, 128.7 (2), 130.4, 133.0, 
139.2, 150.3, 159.7, 160.1. MS m/z (%): 318 (M+) (22.5), 247 
(100). Calculated for C
20
H
22
N
4
 (318): C, 75.44; H, 6.96; N, 
17.60. Found: C, 75.09; H, 6.63; N, 17.92.
N-(2-(1-Methylpyrrolidin-2-yl)ethyl)-2-
phenylquinqzolin-4-amine (5)
Yield, 85%; mp .360°C. IR (cm−1): 3,308 (NH), 3,060 (arom), 
2,950, 2,819, (aliph), 1,618 (CN). 1H-NMR: δ 1.7–2.3 [m, 6H, 
3CH
2
 Cyclo], 1.9 [m, 2H, CH
2
-CH], 2.4 [m, 1H, CH Cyclo], 
2.5 [s, 3H, N-CH
3
], 3.0 [m, 2H, CH
2
-NH], 7.4–8.6 [m, 10H, 
Ar-H + NH]. 13C NMR: δ 21.4, 29.4, 29.5, 40.4, 40.5, 55.2, 
66.0, 114.3, 123.4, 125.7 (2), 128.2, 128.3, 128.7 (2), 130.5, 
133.2, 139.1, 150.3, 159.7, 160.2. MS m/z (%): 332 (M+) 
(21.6), 316 (100). Calculated for C
21
H
24
N
4
 (332): C, 75.87; H, 
7.28; N, 16.85. Found: C, 76.11; H, 7.57; N, 17.20.
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N-(2-(1-Methyl-1h-pyrrol-2-yl)ethyl)-2-
phenylquinqzolin-4-amine (6)
Yield, 82%; mp 172°C–173°C. IR (cm−1): 3,334 (NH), 3,059 
(arom), 2,930, 2,825 (aliph), 1,618 (CN). 1H NMR: δ 1.9 
[s, 3H, CH
3
], 2.8–3.9 [m, 4H, 2CH
2
], 5.6–6.6 [m, 3H, 3CH Pyr-
role], 7.5–8.5 [m, 10H, Ar-H + NH]. 13C NMR: δ 25.9, 33.6, 41.0, 
106.4, 106.7, 114.3, 121.8, 123.0, 125.5, 125.7 (2), 128.1, 128.3, 
128.6 (2), 130.4, 133.1, 133.4, 150.4, 159.8, 162.7. MS m/z (%): 
328 (M+) (3.26), 248 (100). Calculated for C
21
H
20
N
4
 (328): C, 
76.80; H, 6.14; N, 17.06. Found: C, 76.55; H, 6.47; N, 16.81.
1-(3-(2-Phenylquinazolin-4-ylamino)propyl)pyrrolidin-
2-one (7)
Yield, 88%; mp .360°C. IR (cm−1): 3,370 (NH), 3,100 (arom), 
2,932, 2,847, (aliph), 1,654 (CO), 1,572 (CN). 1H NMR: 
δ 1.5–3.2 [m, 6H, 3CH
2
 Cyclo], 1.9 [m, 2H, CH
2
-CH
2
-CH
2
], 
3.3–3.5 [m, 4H, NH-CH
2
 + N-CH
2
], 7.3–8.8 [m, 10H, Ar-H + 
NH]. 13C NMR: δ 18.5, 20.5, 29.1, 40.3, 40.4, 56.5, 114.3, 
123.1, 125.8 (2), 128.3, 128.6, 130.5 (2), 133.1, 135.7, 139.1, 
150.3, 159.6, 160.1, 183.2. MS m/z (%): 346 (M+) (15.38), 317 
(100). Calculated for C
21
H
22
N
4
O (346): C, 72.81; H, 6.40; 
N, 16.17. Found: C, 72.54; H, 6.08; N, 16.46.
N-(1-ethyl-1H-pyrazol-5-yl)-2-phenylquinazolin-4-
amine (8)
Yield, 92%; mp 243°C–244°C. IR (cm−1): 3,414 (NH), 3,062 
(arom), 2,956, 2,854 (aliph), 1,617 (CN). 1H NMR: δ 1.3 
[t, 3H, CH
3
], 4.3 [q, 2H, CH
2
], 7.4–8.5 [m, 11H, Ar-H], 12.5 
[s, 1H, NH]. 13C NMR: δ 16.2, 40.4, 93.8, 114.6, 121.4, 126.3 
(2), 127.0, 127.8, 128.2 (2), 129.0, 131.8, 133.2, 135.0, 149.1, 
152.9, 162.8 (2). MS m/z (%): 315 (M+) (9.54), 286 (100). 
Calculated for C
19
H
17
N
5
 (315): C, 72.36; H, 5.43; N, 22.21. 
Found: C, 72.69; H, 5.16; N, 22.51.
1,5-Dimethyl-2-phenyl-4-(2-phenylquinazolin-4-
ylamino)-1,2-dihydropyrazol-3-one (9)
Yield, 84%; mp 149°C–150°C. IR (cm−1): 3,413 (NH), 3,060 
(arom), 2,923, 2,839, (aliph), 1,654 (CO), 1,618 (CN). 1H NMR: 
δ 2.3 [s, 3H, CH
3
], 3.1 [s, 3H, N-CH
3
], 7.3–8.5 [m, 14H, Ar-H], 
9.4 [s, 1H, NH]. 13C NMR: δ 11.6, 31.2, 114.2 (2), 123.6, 124.0 
(2), 126.2, 126.7 (2), 128.2, 128.4, 128.7 (2), 129.6 (2), 130.6 
(2), 133.5, 135.9, 138.8, 150.8, 159.5, 160.1, 162.7. MS m/z (%): 
407 (M+) (5.98), 331 (100). Calculated for C
25
H
21
N
5
O (407): C, 
73.69; H, 5.19; N, 17.19. Found: C, 73.44; H, 5.50; N, 17.56.
N-(3-(1h-imidazol-1-yl)propyl)-2-phenylquinazolin-4-
amine (10)
Yield, 79%; mp 174°C–175°C. IR (cm−1): 3,231 (NH), 
3,058 (arom), 2,927, 2,866 (aliph), 1,617 (CN). 1H 
NMR: δ 2.1–4.1 [m, 6H, CH
2
-CH
2
-CH
2
-N], 7.2–8.4 [m, 12H, 
Ar-H], 8.5 [s, 1H, NH]. 13C NMR: δ 30.6, 40.5, 44.4, 114.3, 
119.9, 123.1, 125.7 (2), 128.3, 128.6, 128.8, 130.5 (2), 133.1 
(2), 137.8, 139.0, 150.3, 159.6, 160.1. MS m/z (%): 329 (M+) 
(17.23), 288 (100). Calculated for C
20
H
19
N
5
 (329): C, 72.93; 
H, 5.81; N, 21.26. Found: C, 72.71; H, 5.49; N, 20.93.
N-(3-(2-Methylpiperidin-1-yl)propyl)-2- 
phenylquinazolin-4-amine (11)
Yield, 84%; mp 254°C–256°C. IR (cm−1): 3,434 (NH), 3,089 
(arom), 2,957, 2,779, (aliph), 1,633 (CN). 1H NMR: δ 1.2 
[s, 3H, CH
3
], 1.3–2.6 [m, 9H, 4CH
2
 + CH Cyclo], 1.6–3.8 
[m, 6H, 3CH
2
], 7.4–8.9 [m, 9H, Ar-H], 10.8 [s, 1H, NH]. 13C 
NMR: δ 12.3, 22.2, 23.5, 27.9, 34.4, 40.4, 50.1, 55.1, 59.0, 
112.9, 120.9, 125.0 (2), 128.2 (2), 129.3 (2), 129.8, 133.7, 
135.8, 157.6 (2), 160.6. MS m/z (%): 360 (M+) (33.85), 344 
(100). Calculated for C
23
H
28
N
4
 (360): C, 76.63; H, 7.83; N, 
15.54. Found: C, 76.91; H, 7.49; N, 15.22.
2-Phenyl-N-(2-piperidin-1-yl)ethylquinazolin-4-
amine (12)
Yield, 90%; mp 317°C–319°C. IR (cm−1): 3,401 (NH), 3,100 
(arom), 2,936, 2,713 (aliph), 1,630 (CN). 1H NMR: δ 2.2–2.7 
[m, 10H, 5CH
2
 Cyclo], 2.8 [t, 2H, N-CH
2
], 4.3 [s, 2H, 
CH
2
NH], 7.4–9.1 [m, 9H, Ar-H], 10.2 [s, 1H, NH]. 13C NMR: 
δ 24.5, 28.0 (2), 47.4, 50.7, 59.4 (2), 112.6, 120.5, 125.0 (2), 
128.1, 128.2, 129.4 (2), 130.4, 131.5, 133.9, 157.4, 160.2, 
162.8. MS m/z (%): 332 (M+) (45.11), 219 (100). Calculated 
for C
21
H
24
N
4
 (332.20): C, 75.87; H, 7.28; N, 16.85. Found: 
C, 76.11; H, 7.55; N, 17.10.
N-(2-Morpholinoethyl)-2-phenylquinazolin-4-
amine (13)
Yield, 76%; mp 273°C–274°C. IR (cm−1): 3,413 (NH), 3,076 
(arom), 2,927, 2,836 (aliph), 1,599 (CN). 1H NMR: δ 2.3–2.4 
[m, 4H, CH
2
-N-CH
2
 morpholino], 2.5–3.2 [m, 4H, 2CH
2
], 
3.6–4.3 [m, 4H, CH
2
-O-CH
2
], 7.3–8.8 [m, 9H, Ar-H], 10.3 
[s, 1H, NH]. 13C NMR: δ 51.5, 54.9, 55.4 (2), 63.7 (2), 113.3, 
126.9, 127.8 (2), 129.6 (2), 129.8 (2), 133.1 (2), 135.5, 159.1, 
160.2, 163.4. MS m/z (%): 334 (M+) (22.17), 256 (100). 
Calculated for C
20
H
22
N
4
O (334): C, 71.83; H, 6.63; N, 16.75. 
Found: C, 71.50; H, 6.30; N, 16.45.
N-(3-Morpholinopropyl)-2-phenylquinazolin-4-
amine (14)
Yield, 80%; mp 235°C–236°C. IR (cm−1): 3,324 (NH), 3,088 
(arom), 2,954, 2,864 (aliph), 1,610 (CN). 1H NMR: δ 1.8–1.9 
[m, 2H, NH-CH
2
-CH
2
-CH
2
], 2.2–2.3 [m, 4H, CH
2
-N-CH
2
 
morpholino], 3.1 [t, 2H, N-CH
2
], 3.2 [t, 2H, NH-CH
2
], 
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3.8–3.9 [m, 4H, CH
2
-O-CH
2
], 7.5–8.5 [m, 9H, Ar-H], 
11.2 [s, 1H, NH]. 13C NMR: δ 23.7, 40.5, 51.4, 54.3 (2), 
63.6 (2), 113.9, 123.8, 128.8 (2), 128.9 (2), 129.6 (2), 132.7, 
133.1, 135.6, 152.2, 160.3, 161.7. MS m/z (%): 348 (M+) 
(10.62), 221 (100). Calculated for C
21
H
24
N
4
O (348): C, 72.39; 
H, 6.94; N, 16.08. Found: C, 72.08; H, 6.60; N, 16.35.
N-(1-Benzylpiperidin-2-yl)-2-phenylquinazolin-4-
amine (15)
Yield, 83%; mp 250°C–251°C. IR (cm−1): 3,380 (NH), 3,077 
(arom), 2,988, 2,867 (aliph), 1,630 (CN). 1H NMR: δ 2.1–2.8 
[m, 9H, 4CH
2
 + CH Cyclo], 4.3 [s, 2H, CH
2
-Ph], 7.4–8.9 
[m, 14H, Ar-H], 10.2 [s, 1H, NH]. 13C NMR: δ 22.6, 28.0, 
34.5, 50.7, 59.4, 83.2, 112.6, 125.0, 128.2, 129.2 (2), 129.4 
(3), 129.9 (3), 130.4 (2), 131.5, 132.0, 133.9, 136.1, 157.5, 
160.2, 162.8. MS m/z (%): 394 (M+) (5.88), 314 (100). Cal-
culated for C
26
H
26
N
4
 (394.22): C, 79.16; H, 6.64; N, 14.20. 
Found: C, 79.48; H, 6.36; N, 13.83.
6-(2-Penylquinazolin-4-ylamino)hexanoic acid (16a)
Yield, 76%; mp 163°C–165°C. IR (cm−1): 3,438 (OH), 
3,311 (NH), 3,078 (arom), 2,939, 2,854 (aliph), 1,687 
(CO), 1,613 (CN). 1H NMR: δ 1.4–1.8 [m, 6H, 3CH
2
], 
2.2 [t, 2H, CH
2
CO], 3.8 [t, 2H, NH-CH
2
], 7.3–8.8 [m, 
9H, Ar-H], 10.5 [s, 1H, NH], 14.9 [s, 1H, OH]. 13C NMR: 
δ 24.6, 26.3, 28.3, 34.0, 41.9, 112.6, 126.8, 128.2 (2), 129.4 
(2), 129.6 (2), 133.7 (2), 135.8, 157.4 (2), 160.2, 174.8. 
MS m/z (%): 335 (M+) (39.45), 290 (100). Calculated for 
C
20
H
21
N
3
O
2
 (335): C, 71.62; H, 6.31; N, 12.53. Found: C, 
71.29; H, 6.60; N, 12.19.
Biological evaluation
Hepa1c1c7 murine hepatoma cells were grown in a humidi-
fied atmosphere at 37°C, 5% CO
2
. The cell culture medium 
was α-minimum essential medium (α-MEM) and was 
supplemented with 10% (v/v) heat- and charcoal-inactivated 
fetal bovine serum. For evaluation of the potential NQO1 
inducer activity, cells (104 per well) were grown in 96-well 
plates for 24 hours, after which the cell culture medium 
was replaced with fresh medium containing each inducer 
(dissolved in DMSO and diluted in the medium 1:1,000), and 
the cells were grown for a further 48 hours. There were eight 
replicates of each treatment of serial dilutions of inducers. 
The final DMSO concentration in the cell culture medium 
was maintained at 0.1% (v/v) in all wells. At the end of the 
treatment period, cell lysates were prepared in digitonin 
and the specific activity of NQO1 was determined using 
menadione as a substrate as described.23,24 The concentration 
that doubles the specific activity of NQO1 (CD value) was 
used as a measure of inducer potency. Mean values for the 
eight replicate wells are shown for each data point. The 
standard deviation for each data point was within 5% of 
the mean value. The classical NQO1 inducer sulforaphane 
was included as a positive control in each bioassay and was 
consistently giving a CD value of 0.2 µM.
Molecular modeling study
The molecular model of all the new anilinoquinazoline 
derivatives was built using molecular operating environment 
(MOE) software suite Version 10.2008 maintaining all the 
default parameters. The structures’ geometry was optimized, 
and a systematic conformational search was carried out to a 
root mean square gradient of 0.01 Å using the ConfSearch 
module implemented in MOE. Computations were set to be 
performed with the Merck Force Field (MMFF94s). The new 
compounds’ ability to access and block the Nrf2-binding site 
of Keap1 was evaluated by performing a molecular docking 
study using the crystallographic structure of Keap1 obtained 
from the Protein Data Bank (PDB ID: 4IQK). Following 
addition of the missing hydrogens and calculating the partial 
charges of the receptor, validation of the docking has been 
carried out by docking of the native ligand. Afterward, the 
ligands were docked where they were left free to explore all 
conformations possible inside the enzyme. Multiple separate 
docking simulations using default parameters were performed 
followed by choosing the best conformations based on the 
combination of S score data, E conformation, and appropriate 
fitting with the relevant amino acids in the binding pocket.
Results and discussion
chemistry
Novel anilinoquinazoline derivatives 2–16a were prepared 
from the key starting material 4-chloro-2-phenylquinazoline 1 
via reaction with primary amines having side chains bearing 
aliphatic groups (eg, heptane, octane), aromatic groups 
(eg, pyrrolidine, imidazole, piperidine), or substituted aro-
matic rings (eg, methyl pyrrolidine, benzyl piperidine, methyl 
piperidine). Refluxing of 1 with the appropriate amine in 
dry dimethylformamide in the presence of triethylamine as 
a base catalyst furnished the desired corresponding com-
pounds 2–16a (Figures 1 and 2). The proposed structures of 
the products were confirmed by their analytical and spectral 
data. First, the IR of the reaction products showed in all 
compounds an absorption band corresponding to their NH 
function in the region 3,434–3,191 cm−1, in addition to a CN 
band in the region 1,639–1,572 cm−1. Moreover, compounds 
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
4.
36
.5
0.
15
2 
on
 0
7-
Se
p-
20
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Drug Design, Development and Therapy 2016:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2519
nQO1 inducer activity of some novel anilinoquinazoline derivatives
Figure 1 synthesis of derivatives 2–11.
Notes: reagents and conditions: a mixture of 1 (0.01 mol) and different amines (0.012 mol) in dry DMF (10 mL) containing three drops of Et3N was refluxed for 24 hours 
and then left to cool. The solid product formed was collected by filtration and recrystallized from acetic acid.
Abbreviation: DMF, dimethylformamide.
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Figure 2 synthesis of derivatives 13–16.
Notes: reagents and conditions: a mixture of 1 (0.01 mol) and different amines (0.012 mol) in dry DMF (10 mL) containing three drops of Et3N was refluxed for 24 hours 
and then left to cool. The solid product formed was collected by filtration and recrystallized from acetic acid.
Abbreviation: DMF, dimethylformamide.
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7, 9, and 16a showed an extra carbonyl absorption band in 
the region 1,687–1,654 cm−1. Finally, compounds 4–16a 
bearing aliphatic carbon chains showed absorption peaks 
around 2,988–2,713 cm−1. Moreover, 1H NMR of 2–16a 
revealed a singlet signal in the region 9.4–11.2 ppm for the 
NH groups. With regard to compounds 16, 1 was reacted 
with 6-aminocaproic acid with the expected product to be 
the azepan-2-one derivative 16b; however, the hexanoic acid 
derivative 16a was obtained instead. That was revealed on 
the basis of elemental analysis and IR, which showed the 
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presence of OH absorption band at 3,438 cm−1, NH band 
at 3,311 cm−1, and a carbonyl band at 1,687 cm−1. That 
was further confirmed using spectral analysis where 1H 
NMR showed a triplet at 3.8 ppm for the NH-CH
2
, signal at 
10.5 ppm for the NH group, and another signal at 14.9 ppm 
for the OH group. Moreover, 13C NMR of 16a revealed 
signals at 24.6 ppm for CH
2
-CH
2
-COOH, 26.3 ppm for CH
2
-
CH
2
-CH
2
-COOH, 28.3 ppm for NH-CH
2
-CH
2
, 34.0 ppm 
for CH
2
-COOH, 41.9 ppm for NH-CH
2
, and 174.8 ppm for 
CO group.
Biological activity
The ability of the novel compounds to double the activity 
of NQO1 was used as a measure of their inducer potency 
(CD values), and results obtained are presented in Table 1. 
Evaluation of the NQO1 inducer activity showed that com-
pounds 2, 5, and 14 were inactive, whereas compounds 4, 6, 
11, 12, 13, and 16a had weak activity; however, CD value 
was not reached (Figure 3). On the other hand, compounds 
3 (CD =14 µM), 7 (CD =26 µM), and 15 (CD =19 µM) had 
moderate inducer activity. Compounds 8 (CD =5.2 µM) and 
10 (CD =5.5 µM) were of approximately equal potency. 
However, the cell responses to them were very different 
where the dose–response dependency was very clear for com-
pound 8, whereas it was completely absent for compound 10. 
The most potent inducer in this series was compound 9 
(CD =3.9 µM), which also showed a very clear dose response 
with a magnitude of induction of approximately sixfold at 
a concentration of 50 µM.
The anilinoquinazolines represent a new chemical class 
of NQO1 inducers, thus adding to the existing knowledge 
of the diversity of the many chemical scaffolds that have 
been reported to induce this enzyme. The classical NQO1 
inducers are primarily oxidants and electrophiles or other 
compounds that react (or are metabolized to products that 
react) and chemically modify cysteine sensors of Keap1. 
They belong to ten distinct chemical classes: 1) oxidizable 
diphenols, phenylenediamines, and quinones, 2) Michael 
reaction acceptors (olefins or acetylenes conjugated with 
electron-withdrawing groups), 3) isothiocyanates and sul-
foxythiocarbamates, 4) thiocarbamates, 5) dithiolethiones, 
6) conjugated polyenes, 7) hydroperoxides, 8) trivalent 
arsenicals, 9) heavy metals, and 10) vicinal dimercaptans.11 
A new generation of NQO1 inducers is also emerging, that 
of noncovalent small-molecule modulators of the Keap–
Nrf2 protein–protein interaction.16,17,25–27 Although we 
cannot exclude the possibility that the anilinoquinazolines 
could be metabolized to electrophilic species in cells, we 
hypothesize that the anilinoquinazolines themselves may 
have a more unusual mechanism of action, namely, the 
ability to directly disrupt the binding of Keap1 to Nrf2, and 
thus belong to the category of noncovalent inducers. To 
begin testing this hypothesis, we next performed molecular 
modeling studies.
Table 1 nQO1 inducer activity and cD values of the test compounds
Conc (µM) Compound #
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16a
0.1563 nr 1.05 nr nr nr nr nr nr nr nr nr nr nr nr nr
0.3125 nr 1.08 nr nr nr nr nr nr nr nr nr nr nr nr nr
0.625 nr 1.07 nr nr nr nr nr nr nr nr nr nr nr nr nr
0.781 1.25 nr 1.24 1.09 0.97 1.01 1.23 1.34 1.66 1.11 1.01 1.12 1.01 1.04 1.12
1.25 nr 1.19 nr nr nr nr nr nr nr nr nr nr nr nr nr
1.563 1.25 nr 1.3 1.1 0.96 1.01 1.33 1.56 1.78 1.1 1.12 1.17 1.04 1.04 1.14
2.5 nr 1.28 nr nr nr nr nr nr nr nr nr nr nr nr nr
3.125 1.21 nr 1.49 1.12 1.08 1.1 1.57 1.86 1.89 1.2 1.26 1.16 1.06 1.1 1.23
5 nr 1.56 nr nr nr nr nr nr nr nr nr nr nr nr nr
6.25 1.2 nr 1.68 1.2 1.31 1.25 2.12 2.41 2.03 1.3 1.36 1.24 1.11 1.23 1.38
10 nr 1.93 nr nr nr nr nr nr nr nr nr nr nr nr nr
12.5 nr nr 1.76 1.28 1.54 1.48 2.63 3.23 2.1 1.5 nr 1.39 1.1 1.45 1.67
20 nr 2.13 nr nr nr nr nr nr nr nr nr nr nr nr nr
25 nr nr nr nr nr 1.98 3.34 4.74 nr nr nr 1.41 1.06 1.53 2.22
50 nr nr nr nr nr 2.73 4.16 6.45 nr nr nr nr nr nr 3.19
100 nr nr nr nr nr 3.63 4.25 nr nr nr nr nr nr nr 4.02
cDa nr 14 nr nr nr 26 5.2 3.9 5.5 nr nr nr nr nr 19
Note: acD data presented are the averages of three independent experiments, each with eight replicate wells of cells, and sD for each data point was within 5% of the value.
Abbreviations: cD, concentration of the test compound that doubles nQO1 activity; nQO1, naD(P)h:quinone oxidoreductase 1; nr, not recorded; sD, standard 
deviation.
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Molecular modeling
It has been established that binding of Keap1 to Nrf2 pro-
motes its degradation, thus maintaining low levels of expres-
sion of downstream target genes. Several small-molecule 
compounds have been reported to have binding affinity 
to the Keap1 Kelch domain, therefore antagonizing its 
activity.25–27 In order to assess the ability of the newly syn-
thesized compounds to access and block the Kelch domain 
of Keap1, a molecular docking study was performed using 
the crystal structure obtained from the PDB ID: 4IQK using 
MOE software suite Version 10.2008. The key interactions 
detected between the validated native ligand and the receptor 
are found to be arene–cation interaction with Arg415, arene–
arene interaction with Tyr525, and three hydrogen bonds 
with Ser602, Ser508, and Ser555 with S=−13.306 Kcal/mol 
with a root mean square deviation of 0.6635 Kcal/mol/Å 
(Figure 4). Docking of the synthesized compounds revealed 
that binding to Arg415 through an arene–cation interaction 
is an important common interaction among all compounds. 
Moreover, by observing the interactions of compounds 
4–16a, it was found that compounds showing activity have 
a larger number of interactions with the binding site of the 
sensor protein via their side chain or via their main skel-
eton. That may emphasize the role of variation of the side 
chain in either making its own interactions or in pushing the 
phenylquinazoline moiety to more interactions with more 
amino acids.
Finally, it was observed that compound 9 showed the 
best activity (CD =3.9 µM) as well as the best binding 
affinity with S=−11.7347 Kcal/mol. Compound 9 was 
Figure 3 concentration dependence of nQO1 inducer activity of the test com-
pounds.
Notes: hepa1c1c7 cells (104 per well) were grown in 96-well plates for 24 hours. 
The cell culture medium was then replaced with fresh medium containing serial 
dilutions of each inducer, the cells were grown for a further 48 hours, and the 
specific enzyme activity of NQO1 was determined using menadione as a substrate 
in cell lysates. Mean values for eight replicate wells are shown for each data point. 
The standard deviation for each data point was within 5% of the mean value. The 
classical nQO1 inducer sFn was used as a positive control.
Abbreviations: nQO1, naD(P)h:quinone oxidoreductase 1; sFn, sulforaphane.
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Figure 4 interactions of the native ligand with the Kelch domain of Keap1 (PDB iD: 41QK).
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able to make two arene–cation interactions with Arg483. 
Although the Arg involved in compound 9 interactions is 
different from Arg415 that the native ligand interacts with, 
the overlap of 9 over the native ligand showed a change 
in the orientation of the compound to ensure better fit-
ting in the pocket (Figure 5). Moreover, an arene–arene 
interaction is noticed with Tyr525 similar to the native 
ligand. Finally an additional arene–arene interaction is 
noticed with Phe478; that additional interaction may be 
related to the high activity of that compound since it is only 
noticed in the interactions of compound 9 with the sensor 
protein (Figure 6).
Conclusion
This study deals with the synthesis of novel anilinoquinazo-
line derivatives with potential NQO1 inducer activity. Among 
the derivatives 2–16a, 12 compounds showed activity, with 
six of them showing CD values ranging between 3.9 µM 
and 25 µM. Finally, the molecular docking study has shown 
that the most active derivative, compound 9 (CD =3.9 µM), 
showed arene–arene interactions with key amino acids in the 
Nrf2-binding site of Keap1. The obtained results introduce 
compound 9 as a lead for anilinoquinazoline scaffold-based 
Nrf2 activators, thus serving as a starting point for lead 
optimization of new molecules based on the chemotype 
described herein.
Figure 5 Overlap of compound 9 (magenta) over native ligand (cyan) with the 
Kelch domain of Keap1.
Abbreviation: Keap1, Kelch-like ech-associated protein 1.
Figure 6 interactions of compound 9 with the Kelch domain amino acids of Keap1.
Abbreviation: Keap1, Kelch-like ech-associated protein 1.


$UJ
*O\
*O\
$OD*OQ
7\U
$UJ
3KH
1
1
1
1
1+ 2
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
4.
36
.5
0.
15
2 
on
 0
7-
Se
p-
20
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Drug Design, Development and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal
Drug Design, Development and Therapy is an international, peer-
reviewed open-access journal that spans the spectrum of drug design 
and development through to clinical applications. Clinical outcomes, 
patient safety, and programs for the development and effective, safe, 
and sustained use of medicines are a feature of the journal, which 
has also been accepted for indexing on PubMed Central. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Drug Design, Development and Therapy 2016:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
2524
ghorab et al
Acknowledgments
The authors would like to extend their sincere appreciation 
to the Deanship of Scientific Research at King Saud Uni-
versity for funding of this research through the Research 
Group Project number RGP-302. Maureen Higgins and 
Albena T Dinkova-Kostova are grateful to Cancer Research 
UK (C20953/A10270 and C20953/A18644) for financial 
support.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Harman D. Antioxidant supplements: effects on disease and aging in 
the United States population. J Am Aging Assoc. 2000;23(1):25–31.
 2. Fridovich I. Superoxide radical and superoxide dismutases. Annu Rev 
Biochem. 1995;64(1):97–112.
 3. Sies H. Oxidative stress: from basic research to clinical application. 
Am J Med. 1991;91(3C):31S–38S.
 4. Waris G, Ahsan H. Reactive oxygen species: role in the development 
of cancer and various chronic conditions. J Carcinog. 2006;5:14.
 5. Dinkova-Kostova AT, Talalay P. NAD(P)H:quinone acceptor oxi-
doreductase 1 (NQO1), a multifunctional antioxidant enzyme and excep-
tionally versatile cytoprotector. Arch Biochem Biophys. 2010;501(1): 
116–123.
 6. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to 
environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev 
Pharmacol Toxicol. 2007;47(1):89–116.
 7. Ross D. Quinone reductases multitasking in the metabolic world. Drug 
Metab Rev. 2004;36(3–4):639–654.
 8. Talalay P, De Long MJ, Prochaska HJ. Identification of a common 
chemical signal regulating the induction of enzymes that protect against 
chemical carcinogenesis. Proc Natl Acad Sci U S A. 1988;85(21): 
8261–8265.
 9. Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT. Cancer 
chemoprevention mechanisms mediated through the Keap1-Nrf2 
pathway. Antioxid Redox Signal. 2010;13(11):1713–1748.
 10. Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the 
Keap1-Nrf2 pathway in stress response and cancer evolution. Genes 
Cells. 2011;16(2):123–140.
 11. Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-
Nrf2 pathway. Arch Toxicol. 2011;85(4):241–272.
 12. Li J, Ichikawa T, Janicki JS, Cui T. Targeting the Nrf2 pathway against car-
diovascular disease. Expert Opin Ther Targets. 2009;13(7):785–794.
 13. Zhao J, Redell JB, Moore AN, Dash PK. A novel strategy to activate 
cytoprotective genes in the injured brain. Biochem Biophys Res Com-
mun. 2011;407(3):501–506.
 14. Steel R, Cowan J, Payerne E, O’Connell MA, Searcey M. Anti-
inflammatory effect of a cell-penetrating peptide targeting the Nrf2/
Keap1 interaction. ACS Med Chem Lett. 2012;3(5):407–410.
 15. Williamson TP, Amirahmadi S, Joshi G, et al. Discovery of potent, novel 
Nrf2 inducers via quantum modeling, virtual screening, and in vitro 
experimental validation. Chem Biol Drug Des. 2012;80(6):810–820.
 16. Hu L, Magesh S, Chen L, et al. Discovery of a small-molecule inhibitor 
and cellular probe of Keap1-Nrf2 protein-protein interaction. Bioorg 
Med Chem Lett. 2013;23(10):3039–3043.
 17. Zhuang C, Miao Z, Sheng C, Zhang W. Updated research and appli-
cations of small molecule inhibitors of Keap1-Nrf2 protein-protein 
interaction: a review. Curr Med Chem. 2014;21(16):1861–1870.
 18. Nesterova NA, Kovalenko SI, Belenichev IF, Karpenkos OV, 
Sidorova IV. Formation of combinational library of quinazoline-4-
yl-hydrazones with antioxidant activity. Ukraine Med Khim. 2004;6: 
14–21.
 19. Nesterova NA, Kovalenko SI, Karpenkos OV, Belenichev IF. Synthe-
sis and antioxidant activity of 4-arylidenehydrazinoquinazolines. Ukr 
Farmatsevtichnii Zhurnal (Kiev). 2004;22:5–10.
 20. Al-Omar MA, Al-Rashood ST, El-Subbagh HI, Abdel Hamide SG. 
Interaction of 2-thio-4-oxo-quinazoline derivatives with guinea pig liver 
molybdenum hydroxylases, xanthine oxidase and aldehyde oxidase. 
J Biol Sci. 2005;5(3):370–378.
 21. Ghorab MM, Higgins M, Alsaid MS, Arafa RK, Shahat AA, Dinkova-
Kostova AT. Synthesis, molecular modeling and NAD(P)H:quinone 
oxidoreductase 1 inducer activity of novel cyanoenone and enone ben-
zenesulfonamides. J Enzyme Inhib Med Chem. 2014;29(6):840–845.
 22. Ghorab MM, Higgins M, Dinkova-Kostova AT, Alsaid MS, Shahat AA. 
Novel thioureido derivatives carrying thione and sulfonamide moieties 
induce the cytoprotective enzyme NAD(P)H:Quinone oxidoreductase 1. 
Asian J Chem. 2014;26(24):8501–8504.
 23. Prochaska HJ, Santamaria AB. Direct measurement of NAD(P)H:quinone 
reductase from cells cultured in microtiter wells: a screening assay 
for anticarcinogenic enzyme inducers. Anal Biochem. 1988;169(2): 
328–336.
 24. Fahey JW, Dinkova-Kostova AT, Stephenson KK, Talalay P. The 
“Prochaska” microtiter plate bioassay for inducers of NQO1. Methods 
Enzymol. 2004;382:243–258.
 25. Marcotte D, Zeng W, Hus JC, et al. Small molecules inhibit the inter-
action of Nrf2 and the Keap1 Kelch domain through a noncovalent 
mechanism. Bioorg Med Chem. 2013;21(14):4011–4019.
 26. Magesh S, Chen Y, Hu L. Small molecule modulators of Keap1-Nrf2-
ARE pathway as potential preventive and therapeutic agents. Med Res 
Rev. 2012;32(4):687–726.
 27. Bertrand HC, Schaap M, Baird L, et al. Design, synthesis, and evaluation 
of triazole derivatives that induce Nrf2 dependent gene products and 
inhibit the Keap1-Nrf2 protein-protein interaction. J Med Chem. 2015; 
58(18):7186–7194.
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
4.
36
.5
0.
15
2 
on
 0
7-
Se
p-
20
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
